Study of JS203 combination therapy for B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination treatment for a type of lymphoma (B-cell non-Hodgkin's lymphoma) that has a protein called CD20 on its cells. It may be an option if you have not received certain previous therapies and your lymphoma is measurable, to see if the combination can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- You have been diagnosed with B-cell non-Hodgkin's lymphoma that has the CD20 protein
- You have at least one tumor that can be measured on scans
- You have not had a severe allergic reaction to antibody treatments before
- You have not had a bone marrow or organ transplant, or specific bispecific antibody therapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called MBS303 to see how safe it is and how well it works in adults with B-cell non-Hodgkin lymphoma (NHL) that has come back or did not respond to prior anti-CD20 treatment. It may help people who have few or no treatment options expected to improve survival.
This study tests a new combination of two drugs (JS004 plus toripalimab) versus standard chemotherapy for people with Hodgkin lymphoma that no longer responds to PD-1/PD-L1 immunotherapy. The goal is to see if the new combination works better.
This trial tests a new treatment called JCXH-213 for people with B-cell non-Hodgkin lymphoma that came back or didn't get better after previous treatment. It aims to see if the treatment is safe and works against the cancer.
This trial tests a new drug called JS207 for people with advanced non-small cell lung cancer (NSCLC) that has gotten worse after standard treatments like chemotherapy and immunotherapy. It aims to see if JS207 can help shrink tumors or slow the cancer's growth.
This trial tests a new combination of drugs (JS212 plus another medicine) for people with advanced esophageal squamous cell carcinoma who have not had prior treatment. It aims to see if the combination is safe and effective.
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
Hear when a new B-cell Non-Hodgkin's Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.